Fujifilm

Company

Also known as: Fujifilm, Fujifilm Holdings, FUJIFILM Holdings

Company Profile

Fujifilm is a Japanese multinational conglomerate operating across imaging, document solutions, medical systems, biotechnology, and related chemical technologies. Founded in 1934 and headquartered in Tokyo, it evolved from photographic film into diversified healthcare and industrial businesses. The company is publicly traded in Japan under ticker 4901.

Website: https://holdings.fujifilm.com
Headquarters: Tokyo, Japan
Founded: 1934
Stock Ticker: TYO:4901

Related News

Japan's Regenerative Cell Therapy Push Advances With Regulatory Review, Market Growth, and New Patents

Jun 11, 2026

Japan's health ministry panel is reviewing two regenerative cell therapies for Parkinson's disease and heart failure, testing the country's push to build a domestic cell-based treatment industry. Japan's cell culture market is projected to reach USD 2.34 billion by 2031, driven by government support and favorable regulatory pathways. Australian firm Cartherics secured a Japanese patent for its iPSC-based immune cell therapies.

FDA extends review of Savara's MOLBREEVI application in autoimmune PAP

Apr 17, 2026

The FDA extended by three months the review period for Savara's MOLBREEVI biologics license application in autoimmune pulmonary alveolar proteinosis, moving the PDUFA date to Nov. 22, 2026. Savara had previously said the FDA filed the application after a resubmission tied to manufacturing data and a transfer to Fujifilm.

Fujifilm Opens UK's Largest Single-Use Biopharma CDMO Facility

Mar 23, 2026

Fujifilm Biotechnologies has opened the UK's largest single-use biopharmaceutical CDMO facility in Teesside with a £400 million investment. The 110,000 sq ft facility features 19,000 liters of bioreactor capacity and will be operational in H1 2026. The expansion includes a new Bioprocess Innovation Centre that doubles the site's lab footprint.

FDA Accepts Savara's MOLBREEVI Application for Rare Lung Disease with August Decision Date

Feb 16, 2026

Savara Inc. announced the FDA has accepted its resubmitted Biologics License Application for MOLBREEVI, a treatment for autoimmune pulmonary alveolar proteinosis, with Priority Review granted and a target decision date of August 22, 2026.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07587619	Intraoperative Use of Oxygen Saturation Imaging to Assess Intestinal Perfusion	ACTIVE_NOT_RECRUITING	PHASE1/PHASE2